Oncopharmpod
Bad News For Belantamab-Mafodotin And Atezolizumab's Bladder Cancer Indication
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:13:54
- Mas informaciones
Informações:
Sinopsis
Recent voluntary withdrawals from the US market of belantamab-mafodotin and atezolizumab's indication for bladder cancer have us weighing (again) the pros & cons of the accelerated approval program. Also, FDA approves the 1st fecal transplant product.
